U.S. patent application number 10/931033 was filed with the patent office on 2005-02-03 for 4-substituted piperidine compound.
This patent application is currently assigned to EISAI CO., LTD.. Invention is credited to Iimura, Yoichi, Kosasa, Takashi.
Application Number | 20050026895 10/931033 |
Document ID | / |
Family ID | 18686313 |
Filed Date | 2005-02-03 |
United States Patent
Application |
20050026895 |
Kind Code |
A1 |
Iimura, Yoichi ; et
al. |
February 3, 2005 |
4-Substituted piperidine compound
Abstract
The present invention provides a novel compound having a
superior acetylcholinesterase inhibitory action. It provides a
compound represented by the formula: 1 (In the formula, R.sup.1
represents a group represented by the formula: 2 (wherein, R.sup.3,
R.sup.4, R.sup.5 and R.sup.6 are the same as or different from each
other and each represents a hydrogen atom, an optionally
substituted C.sub.1-6 alkoxy group and the like; and m represents
an integer from 0 to 6) and the like; and R.sup.2 represents a
hydrogen atom, an optionally substituted C.sub.1-6 alkyl group, an
optionally substituted C.sub.2-6 alkenyl group or an optionally
substituted C.sub.2-6 alkynyl group), a salt thereof or a hydrate
of them.
Inventors: |
Iimura, Yoichi; (Ibaraki,
JP) ; Kosasa, Takashi; (Ibaraki, JP) |
Correspondence
Address: |
BIRCH STEWART KOLASCH & BIRCH
PO BOX 747
FALLS CHURCH
VA
22040-0747
US
|
Assignee: |
EISAI CO., LTD.
|
Family ID: |
18686313 |
Appl. No.: |
10/931033 |
Filed: |
September 1, 2004 |
Related U.S. Patent Documents
|
|
|
|
|
|
Application
Number |
Filing Date |
Patent Number |
|
|
10931033 |
Sep 1, 2004 |
|
|
|
10296379 |
Nov 25, 2002 |
|
|
|
10296379 |
Nov 25, 2002 |
|
|
|
PCT/JP01/05320 |
Jun 21, 2001 |
|
|
|
Current U.S.
Class: |
514/183 ;
514/217.01; 514/314; 514/319; 514/321; 514/323 |
Current CPC
Class: |
A61P 25/28 20180101;
C07D 211/32 20130101; A61P 43/00 20180101; A61P 25/14 20180101 |
Class at
Publication: |
514/183 ;
514/217.01; 514/314; 514/319; 514/323; 514/321 |
International
Class: |
A61K 031/55; A61K
031/4709; A61K 031/454 |
Foreign Application Data
Date |
Code |
Application Number |
Jun 21, 2000 |
JP |
2000-186085 |
Claims
1. A method for treating a disease or condition against which an
acetylcholinesterase inhibitory action is efficacious, said method
comprising: administering a therapeutically effective amount of a
compound, a salt thereof, or a hydrate of said compound or salt
thereof to a patient in need thereof, wherein said compound is
represented by the formula: 21wherein R.sup.2 of formula (I)
represents a hydrogen atom, an optionally substituted C.sub.1-6
alkyl group, an optionally substituted C.sub.1-6 alkenyl group or
an optionally substituted C.sub.1-6 alkynyl group, a salt thereof,
or a hydrate of said compound or salt thereof; and R.sup.1 of
formula (I) represents any one of group selected from the group
consisting of the formulae: 2223wherein R.sup.3, R.sup.4, R.sup.5
and R.sup.6 are the same as or different from each other and each
represents a hydrogen atom, a halogen atom, a hydroxyl group, an
optionally substituted hydrocarbon group, an optionally substituted
C.sub.1-6 alkoxy group, a C.sub.1-6 acyl group, a nitro group, an
optionally substituted amino group, an optionally substituted amide
group, a mercapto group or a C.sub.1-6 thioalkoxy group; R.sup.7
represents a hydrogen atom or a C.sub.1-6 alkyl group; the partial
structure represents a single bond or a double bond; m is 0 or an
integer from 1 to 6; and p represents an integer of 1 or 2.
2. The method of claim 1, wherein said R.sup.1 in said formula (1)
of the compound, a salt thereof, or a hydrate of said compound or
salt thereof, is a group selected from the group of formulae
consisting of 24wherein R.sup.3, R.sup.4, R.sup.5 and R.sup.6 are
the same as or different from each other and each represents a
hydrogen atom, a halogen atom, a hydroxyl group, an optionally
substituted hydrocarbon group, an optionally substituted C.sub.1-6
alkoxy group, a C.sub.1-6 acyl group, a nitro group, an optionally
substituted amino group, an optionally substituted amide group, a
mercapto group or a C.sub.1-6 thioalkoxy group; and m is 0 or an
integer from 1 to 6.
3. The method of claim 1 or 2, wherein said wherein said
substituent in the optionally substituted C.sub.1-6 alkyl group,
optionally substituted C.sub.2-6 alkenyl group or optionally
substituted C.sub.2-6 alkynyl group of R.sup.2 of the compound, a
salt thereof, or a hydrate of said compound or salt thereof, is at
least one selected from the group consisting of a halogen atom, a
hydroxyl group, a nitrile group, a C.sub.1-6 alkyl group, C.sub.3-8
cycloalkyl group, a C.sub.1-6 alkoxy group, a C.sub.1-6
alkoxyalkoxy group, an aryloxy group, an aralkyloxy group, a
halogenated C.sub.1-6 alkyl group, a hydroxy C.sub.1-6 alkyl group,
a cyano C.sub.1-6 alkyl group, a halogenated C.sub.1-6 alkoxy
group, a hydroxy C.sub.1-6 alkoxy group, a cyano C.sub.1-6 alkoxy
group, a C.sub.1-6 acyl group, a nitro group, an optionally
substituted amino group, an optionally substituted amide group, a
mercapto group and a C.sub.1-6 thioalkoxy group.
4. The method of claim 1 or 2, wherein said R.sup.3, R.sup.4,
R.sup.5 and R.sup.6 in formula (1) of the compound, a salt thereof,
or a hydrate of said compound or salt thereof, are the same as or
different from each other and each represents a hydrogen atom or an
optionally substituted C.sub.1-6 alkoxy group.
5. The method according to claim 1 or 2, wherein said R.sup.3,
R.sup.4, R.sup.5 and R.sup.6 in formula (1) of the compound, a salt
thereof, or a hydrate of said compound or salt thereof, are the
same as or different from each other and each represents a hydrogen
atom or an optionally substituted methoxy group.
6. The method according to claim 1 or 2, wherein m of formula (1)
of the compound, a salt thereof, or a hydrate of said compound or
salt thereof, is an integer of 1.
7. The method according to claim 1, wherein R.sup.1 of formula (1)
of the compound, a salt thereof, or a hydrate of said compound or
salt thereof, is a [(5,6-dimethoxy-2-fluoro-1-indanon)-2-yl]methyl
group.
8. The method according to claim 1 or 2, wherein R.sup.2 of formula
(1) of the compound, a salt thereof, or a hydrate of said compound
or salt thereof, is a hydrogen atom.
9. The method according to claim 1 or 2, wherein R.sup.2 of formula
(1) of the compound, a salt thereof, or a hydrate of said compound
or salt thereof, is an optionally substituted C.sub.1-6 alkyl
group.
10. The method according to claim 1 or 2, wherein R.sup.2 of
formula (1) of the compound, a salt thereof, or a hydrate of said
compound or salt thereof, is a C.sub.1-6 alkyl group substituted
with (1) a halogen atom, (2) a hydroxyl group or (3) a nitrile
group.
11. The method according to claim 1 or 2, wherein R.sup.2 of
formula (1) of the compound, a salt thereof, or a hydrate of said
compound or salt thereof, is a methyl group, an ethyl group, a
n-propyl group, an iso-propyl group, a 2-methyl-1-propyl group or a
tert-butyl group.
12. The method according to claim 1, wherein said compound, a salt
thereof, or a hydrate of said compound or salt thereof, is
4-[(5,6-dimethoxy-2-fluoro-1-indanon)-2-yl]methylpiperidine,
4-[(5,6-dimethoxy-2-fluoro-1-indanon)-2-yl]methyl-1-methylpiperidine,
4-[(5,6-dimethoxy-2-fluoro-1-indanon)-2-yl]methyl-1-(1-methylethyl)piperi-
dine or
4-[(5,6-dimethoxy-2-fluoro-1-indanon)-2-yl]methyl-1-(2-methylpropy-
l)piperidine.
13. The method according to claim 1 or 2, wherein the disease or
condition is senile dementia, cerebrovascular dementia or attention
deficit hyperactivity disorder.
Description
CROSS-REFERENCE TO RELATED APPLICATIONS
[0001] The present application is a 37 C.F.R. .sctn. 1.53(b)
Divisional of U.S. application Ser. No. 10/296,379, filed Nov. 25,
2002, which is the National Phase under 35 U.S.C. .sctn. 371 of PCT
International Application No. PCT/JP01/05320, which has an
international filing date of Jun. 21, 2001, which in turn claims
priority on Japanese Application No. 2000-186085 filed Jun. 21,
2000. Each of the above applications are hereby incorporated by
reference.
FIELD OF THE INVENTION
[0002] The present invention relates to a novel compound useful as
an acetylcholinesterase inhibitor, a salt thereof or a hydrate of
them, and to a process for producing it.
PRIOR ART
[0003] It has been known that senile dementia such as
Alzheimer-type senile dementia, cerebrovascular dementia, attention
deficit hyperactivity disorder and the like are accompanied by a
reduction in cholinergic functions in the brain. At present, it has
been recognized that acetylcholinesterase inhibitors are effective
as an agent for treating these diseases, and actually, they have
been clinically applied. In addition to its typical therapeutic
agent, Donepezil Hydrochloride
(1-benzyl-4-[(5,6-dimethoxy-1-indanon)-2-yl]methylpiperidine
hydrochloride), for example, Rivastigmine
(3-[1-(dimethylamino)ethyl]phen- yl N-ethyl-N-methylcarbamate),
Metrifonate (dimethyl (2,2,2-trichloro-1-hydroxyethyl)phosphate),
Tacrine Hydrochloride (1,2,3,4-tetrahydro-9-acridinamine),
Galanthamine Hydrobromide, Neostigmine and Physostigmine are
known.
[0004] However, among the above-mentioned therapeutic agents,
Donepezil Hydrochloride is the only one that has been actually
clinically applied and has been recognized as useful in points of
pharmacological activities against the disease, side effects,
administrations times, administration forms etc. Further, except
for this agent, no acetylcholinesterase inhibitors being clinically
useful have been found. Therefore, there have been strong demands
for useful acetylcholinesterase inhibitors having superior effects
other than Donepezil Hydrochloride.
DISCLOSURE OF THE INVENTION
[0005] Under such circumstances, the present inventors have
extensively studied for a long period of time. As a result, they
have successfully synthesized a novel compound represented by the
formula: 3
[0006] in the formula, R.sup.1 represents any one of group selected
from the group consisting of the formulae: 45
[0007] (in the formulae, R.sup.3, R.sup.4, R.sup.5 and R.sup.6 are
the same as or different from each other and each represents a
hydrogen atom, a halogen atom, a hydroxyl group, an optionally
substituted hydrocarbon group, an optionally substituted C.sub.1-6
alkoxy group, a C.sub.1-6 acyl group, a nitro group, an optionally
substituted amino group, an optionally substituted amide group, a
mercapto group or a C.sub.1-6 thioalkoxy group; R.sup.7 represents
a hydrogen atom or a C.sub.1-6 alkyl group; a bond represented by
the partial structure may be a single bond or a double bond; m is 0
or an integer from 1 to 6; and p represents an integer of 1 or 2);
and R.sup.2 represents a hydrogen atom, an optionally substituted
C.sub.1-6 alkyl group, an optionally substituted C.sub.2-6 alkenyl
group or an optionally substituted C.sub.2-6 alkynyl group.
Further, they have found unexpectedly that the compound, a salt
thereof and a hydrate of them have a superior acetylcholinesterase
inhibitory action, and make it possible to achieve the initial
objective. Thus, they have accomplished the present invention.
[0008] That is, the present invention relates to (1) a compound
represented by the above formula (I), a salt thereof or a hydrate
of them. Further, (2) in the above-mentioned (1), R.sup.1 may be a
group represented by the formula: 6
[0009] (in the formula, R.sup.3, R.sup.4, R.sup.5, R.sup.6 and m
are have the same meanings as defined in the above-mentioned (1));
(3) in the above-mentioned (1) or (2), R.sup.3, R.sup.4, R.sup.5
and R.sup.6 may be the same as or different from each other and
each may be a hydrogen atom or an optionally substituted C.sub.1-6
alkoxy group; (4) in the above-mentioned (1) or (2), R.sup.3,
R.sup.4, R.sup.5 and R.sup.6 may be the same as or different from
each other and each may be a hydrogen atom or an optionally
substituted methoxy group; (5) in the above-mentioned (1) or (2), m
may be an integer of 1; (6) in the above-mentioned (1), R.sup.1 may
be [(5,6-dimethoxy-2-fluoro-1-indanon)-2-yl]methyl group; (7) in
the above-mentioned (1) or (2), R.sup.2 may be a hydrogen atom; (8)
in the above-mentioned (1) or (2), R.sub.2 may be an optionally
substituted C.sub.1-6 alkyl group; (9) in the above-mentioned (1)
or (2), R.sup.2 may be a C.sub.1-6 alkyl group which may be
substituted with 1) a halogen atom, 2) a hydroxyl group or 3) a
nitrile group; (10) in the above-mentioned (1) or (2), R.sup.2 may
be a methyl group, an ethyl group, a n-propyl group, an iso-propyl
group, a 2-methyl-1-propyl group or a tert-butyl group; and (11) in
the above-mentioned (1), the compound may be
4-[(5,6-dimethoxy-2-fluoro-1-indanon)-2-yl]methylpiperidine,
4-[(5,6-dimethoxy-2-fluoro-indanon)-2-yl]methyl-1-methylpipe
ridine,
4-[(5,6-dimethoxy-2-fluoro-1-indanon)-2-yl]methyl-1-(1-methylethyl)piperi-
dine or
4-[(5,6-dimethoxy-2-fluoro-1-indanon)-2-yl]methyl-1-(2-methylpropy-
l)piperidine. Moreover, the present invention relates to (12) a
medicine comprising the compound described in the above-mentioned
(1), a salt thereof or a hydrate of them. Further, (13) in the
above-mentioned (12), the medicine may be an acetylcholinesterase
inhibitor; (14) in the above-mentioned (12), the medicine may be an
agent for treating, preventing or improving senile dementia,
cerebrovascular dementia or attention deficit hyperactivity
disorder; and (15) in the above-mentioned (14), the senile dementia
may be Alzheimer-type senile dementia. Further, the present
invention also relates to (16) a process for producing the compound
described in the above (1), a salt thereof or a hydrate of them,
which comprises fluorinating a 4-substituted piperidine compound
represented by the formula: 7
[0010] (in the formula, R.sup.11 represents any one of group
selected from the group consisting of the following substituents:
89
[0011] (wherein, R.sup.3, R.sup.4, R.sup.5, R.sup.6, R.sup.7, m, p
and a bond represented by the partial structure have the same
meanings as defined in the above (1), respectively); and R.sup.2
has the same meaning as defined in the above (1)); and, if
necessary, converting it into a salt; and (17) in the producing
process described in the above-mentioned (16), the fluorinating
agent maybe N-fluorobenzenesulfoneimide,
3-cyclohexyl-2-fluoro-2,3-dihydro-3-methyl-1,1-dioxide-1,2-benzisothiazol-
e or
2-fluoro-3,3-dimethyl-2,3-dihydro-1,2-benzisothiazole-1,1-dioxide.
[0012] The present invention provides a method for preventing,
treating or improving a disease against which an
acetylcholinesterase inhibitory action is efficacious, by
administering a pharmacologically effective dose of the compound
represented by the above-mentioned formula (I), a salt thereof or a
hydrate of them to a patient.
[0013] The present invention provides use of the compound
represented by the above-mentioned formula (I), a salt thereof or a
hydrate of them, for producing an agent for preventing, treating or
improving a disease against which an acetylcholinesterase
inhibitory action is efficacious.
[0014] In the present invention, those diseases against which an
acetylcholinesterase inhibitory action is efficacious include
senile dementia such as Alzheimer-type senile dementia,
cerebrovascular dementia and attention deficit hyperactivity
disorder.
DETAILED DESCRIPTION OF THE INVENTION
[0015] Hereinafter, the symbols, terms etc. used in the present
specification are explained and the present invention is
illustrated in more detail.
[0016] In the present specification, the structural formula of a
compound may represent a certain isomer for the sake of
convenience, however, the present invention includes isomers such
as all geometric isomers resulted from the structure of the
compound, optical isomers due to asymmetric carbon, stereo isomers
and tautomers, and a mixture of isomers. Further, it is not limited
to the description of the formula given for the sake of
convenience, and may be either one of isomers or a mixture thereof.
Accordingly, the compound of the present invention may contain an
asymmetric carbon atom in molecule so that an optical active
compound and a racemic compound may be present. However, the
present invention is not limited thereto, but includes any of them.
Further, crystal polymorphism may be present. However, the present
invention is not limited thereto, but any of crystal forms may be
single or a mixture of crystal forms. The compound (I) according to
the present invention or a salt thereof may be either an anhydride
or a hydrate, and any of these are included in the scope of claims
of the present invention. The metabolite generated by decomposing
the compound (I) according to the present invention in vivo, and
the prodrug of the compound (I) of the present invention or a salt
thereof are also included in the scope of claims of the present
invention.
[0017] Definition of R.sup.1
[0018] In the definition of R.sup.1 in the above formula (I),
"halogen atoms" represented by R.sup.3, R.sup.4, R.sup.5 and
R.sup.6 mean, for example, fluorine atoms, chlorine atoms, bromine
atoms and iodine atoms, and preferably fluorine atoms, chlorine
atoms and bromine atoms.
[0019] The "hydrocarbon groups" in "optionally substituted
hydrocarbon groups" represented by R.sup.3, R.sup.4, R.sup.5 and
R.sup.6 mean chain hydrocarbon groups such as C.sub.1-6 alkyl
groups or cyclic hydrocarbon groups such as C.sub.3-8 cycloalkyl
groups. The "C.sub.1-6 alkyl groups" represented by R.sup.3,
R.sup.4, R.sup.5, R.sup.6 and R.sup.7 mean alkyl groups having 1 to
6 carbon atoms, and for example, linear or branched alkyl groups,
such as methyl group, ethyl group, n-propyl group, iso-propyl
group, n-butyl group, iso-butyl group, tert-butyl group, n-pentyl
group, iso-pentyl group, neopentyl group, hexyl group,
1-methylpropyl group, 1-methylbutyl group or 2-methylbutyl group
may be proposed.
[0020] The "C.sub.3-8 cycloalkyl groups" represented by R.sup.3,
R.sup.4, R.sup.5 and R.sup.6 mean cyclic alkyl groups having 3 to 8
carbon atoms. For example, cyclopropyl group, cyclobutyl group,
cyclopentyl group, cyclohexyl group, cycloheptyl group, cyclooctyl
group etc. may be proposed.
[0021] The "C.sub.1-6 cycloalkoxy groups" represented by R.sup.3,
R.sup.4, R.sup.5 and R.sup.6 mean groups in which the group having
the same meaning as the "C.sub.1-6 alkyl group" defined above is
bound to an oxygen atom. For example, linear or branched alkoxy
groups such as methoxy group, ethoxy group, n-propoxy group,
iso-propoxy group, n-butoxy group, iso-butoxy group, tert-butoxy
group, pentyloxy group or hexyloxy group may be proposed.
[0022] The "C.sub.1-6 alkoxyalkoxy groups" represented by R.sup.3,
R.sup.4, R.sup.5 and R.sup.6 mean groups in which the "C.sub.1-6
alkoxy group" is further bound to the group having the same meaning
as the C.sub.1-6 alkyl group defined above. For example,
methoxymethoxy group, methoxyethoxy group, methoxypropoxy group,
ethoxymethoxy group, ethoxyethoxy group, ethoxypropoxy group,
propoxypropoxy group etc. may be proposed.
[0023] The "halogenated C.sub.1-6 alkyl groups" represented by
R.sup.3, R.sup.4, R.sup.5 and R.sup.6 mean groups in which one or
not less than two halogen atoms that are the same as or different
from each other are bound to the "C.sub.1-6 alkyl group" having the
same meaning as the C.sub.1-6 alkyl group defined above. For
example, chloromethyl group, dichloromethyl group, trichloromethyl
group, fluoromethyl group, difluoromethyl group, trifluoromethyl
group and fluoroethyl group, difluoroethyl group, trifluoroethyl
group etc. may be proposed.
[0024] The "hydroxy-C.sub.1-6 alkyl groups" represented by R.sup.3,
R.sup.4, R.sup.5 and R.sup.6 mean groups in which one or not less
than two hydroxyl groups are bound to the group having the same
meaning as the C.sub.1-6 alkyl group defined above. For example,
hydroxymethyl group, hydroxyethyl group, 2,3-dihydroxypropyl group
etc. may be proposed.
[0025] The "cyano C.sub.1-6 alkyl groups" represented by R.sup.3,
R.sup.4, R.sup.5 and R.sup.6 mean groups in which one or not less
than two cyano groups are bound to the group having the same
meaning as the C.sub.1-6 alkyl group defined above. Specific
examples thereof include cyanomethyl group, cyanoethyl group and
cyanopropyl group.
[0026] The "halogenated C.sub.1-6 alkoxy groups" represented by
R.sup.3, R.sup.4, R.sup.5 and R.sup.6 mean groups in which the
"halogenated C.sub.1-6 alkyl group" having the same meaning as the
halogenated C.sub.1-6 alkyl group defined above is bound to an
oxygen atom, the "hydroxy C.sub.1-6 alkoxy groups" mean groups in
which the "hydroxy C.sub.1-6 alkyl group" having the same meaning
as the hydroxy C.sub.1-6 alkyl group defined above is bound to an
oxygen atom, and the "cyano C.sub.1-6 alkoxy groups" mean groups in
which the "cyano C.sub.1-6 alkyl group" having the same meaning as
the cyano C.sub.1-6 alkyl group defined above is bound to an oxygen
atom.
[0027] The "C.sub.1-6 acyl groups" represented by R.sup.3, R.sup.4,
R.sup.5 and R.sup.6 mean linear or branched acyl groups derived
from fatty acids having 1 to 6 carbon atoms. For example, formyl
group, acetyl group, propionyl group, butyryl group, isobutyryl
group, valeryl group, isovaleryl group, pivaloyl group and hexanoyl
group may be proposed.
[0028] The "optionally substituted amino groups" represented by
R.sup.3, R.sup.4, R.sup.5 and R.sup.6 mean amino groups in which
the nitrogen atom may be substituted with a group such as a
C.sub.1-6 alkyl group, and the amino groups also include cyclic
amino groups. As the "optionally substituted amino groups", for
example, amino group (--NH.sub.2), methyl amino group
(--NHCH.sub.3), dimethyl amino group (--N(CH.sub.3).sub.2),
pyrrolidinyl group, pyrazolinyl group, piperidyl group and
piperazinyl group may be proposed.
[0029] The "optionally substituted amide groups" represented by
R.sup.3, R.sup.4, R.sup.5 and R.sup.6 mean amide groups in which
the nitrogen atom may be substituted with a group such as a
C.sub.1-6 alkyl group, and the amide groups also include amide
groups of cyclic amine. As the "optionally substituted amide
groups", for example, amide group (--CONH.sub.2), N-methylamide
group (--CONHCH.sub.3), N,N-dimethylamide group
(--CON(CH.sub.3).sub.2), N-ethylamide group (--CONHC.sub.2H.sub.5),
N,N-diethylamide group (--CON(C.sub.2H.sub.5).sub.2),
N-methyl-N-ethylamide group (--CON(CH.sub.3)C.sub.2H.sub.5),
pyrrolidinylcarbonyl group, pyrazolinylcarbonyl group,
piperidylcarbonyl group and piperazinylcarbonyl group may be
proposed.
[0030] The "C.sub.1-6 thioalkoxy groups" represented by R.sup.3,
R.sup.4, R.sup.5 and R.sup.6 mean groups in which the group having
the same meaning as the C.sub.1-6 alkyl group defined above is
bound to a sulfur atom. For example, methylthio group (--SCH.sub.3)
and ethylthio group (--SC.sub.2H.sub.5) may be proposed.
[0031] In the definition of R.sup.1 in the above formula (I),
symbol m indicates 0 or an integer from 1 to 6, and m is preferably
0 or an integer from 1 to 5, more preferably 0 or an integer from 1
to 3, further preferably 0 or an integer of 1 or 2, and the most
preferably 0 or 1. Moreover, symbol p represents an integer of 1 or
2, and preferably 1.
[0032] In the above formula (I), R.sup.1 may be any group selected
from the group consisting of the groups shown below: 1011
[0033] and preferably a group represented by the formula: 12
[0034] in the formula, R.sup.3, R.sup.4, R.sup.5 and R.sup.6 and m
have the same meanings as defined above. In this case, preferably,
R.sup.3, R.sup.4, R.sup.5 and R.sup.6 are the same as or different
from each other and each represents a hydrogen atom, a halogen
atom, a hydroxyl group, a C.sub.1-6 alkyl group, a C.sub.1-6 alkoxy
group, a halogenated C.sub.1-6 alkyl group, a hydroxy C.sub.1-6
alkyl group, a cyano C.sub.1-6 alkyl group, a halogenated C.sub.1-6
alkoxy group, a hydroxy C.sub.1-6 alkoxy group, a cyano C.sub.1-6
alkoxy group; and m is 0 or an integer from 1 to 5. More
preferably, R.sup.3, R.sup.4, R.sup.5 and R.sup.6 are the same as
or different from each other and each represents a hydrogen atom, a
C.sub.1-6 alkoxy group, a halogenated C.sub.1-6 alkoxy group, a
hydroxy C.sub.1-6 alkoxy group or a cyano C.sub.1-6 alkoxy group;
and m is 0 or an integer from 1 to 3. Further preferably, R.sup.3,
R.sup.4, R.sup.5 and R.sup.6 are the same as or different from each
other and each represents a hydrogen atom or a C.sub.1-6 alkoxy
group (for example, a methoxy group, ethoxy group, n-propoxy group
and i-propoxy group); and m is 1 or 2. The most preferably, R.sup.3
and R.sup.6 are hydrogen atoms; R.sup.4 and R.sup.5 are C.sub.1-6
alkoxy groups which are the same as or different from each other
(for example, methoxy group, ethoxy group, n-propoxy group and
i-propoxy group); and m is 1 or 2. As R.sup.1,
[(5,6-dimethoxy-2-fluoro-1-indanon)-2-yl]methyl group is the most
preferred.
[0035] Definition of R.sup.2
[0036] In the above formula (I), the "C.sub.1-6 alkyl groups" in
the "optionally substituted C.sub.1-6 alkyl groups" represented by
R.sup.2 have the same meaning as the C.sub.1-6 alkyl group defined
above. For example, linear or branched alkyl groups such as methyl
group, ethyl group, n-propyl group, i-propyl group, n-butyl group,
i-butyl group, tert-butyl group, n-pentyl group, i-pentyl group,
neopentyl group, n-hexyl group, 1-methylpropyl group,
1,2-dimethylpropyl group, 2-ethylpropyl group,
1-methyl-2-ethylpropyl group, 1-ethyl-2-methylpropyl group,
1,1,2-trimethylpropyl group, 1-methylbutyl group, 2-methylbutyl
group, 1,1-dimethylbutyl group, 2,2-dimethylbutyl group,
2-ethylbutyl group, 1,3-dimethylbutyl group, 2-methylpentyl group
or 3-methylpentyl group, and preferably, methyl group, ethyl group,
n-propyl group, i-propyl group, 2-methyl-1-propyl group and t-butyl
group may be proposed.
[0037] The "C.sub.2-6 alkenyl groups" in the "optionally
substituted C.sub.2-6 alkenyl groups" represented by R.sup.2 refer
to alkenyl groups having 2 to 6 carbon atoms. For example, linear
or branched C.sub.2-6 alkenyl groups such as vinyl group, allyl
group, 1-propenyl group, isopropenyl group, 1-buten-1-yl group,
1-buten-2-yl group, 1-buten-3-yl group, 2-buten-1-yl group or
2-buten-2-yl group, and preferably, vinyl group, allyl group and
isopropenyl group may be proposed.
[0038] The "C.sub.2-6 alkynyl groups" in the "optionally
substituted C.sub.1-6 alkynyl groups" represented by R.sup.2 refer
to alkynyl groups derived from alkyne having 2 to 6 carbon atoms.
For example, linear or branched C.sub.2-6 alkynyl groups such as
ethynyl group, 1-propynyl group, 2-propynyl group, butynyl group,
pentynyl group and hexynyl group.
[0039] As the "substituent" in the "optionally substituted
C.sub.1-6 alkyl groups", "optionally substituted C.sub.1-6 alkenyl
groups" and "optionally substituted C.sub.1-6 alkynyl groups"
represented by R.sup.2, for example, a halogen atom, a hydroxyl
group, a nitrile group, a C.sub.1-6 alkyl group, C.sub.3-8
cycloalkyl group, a C.sub.1-6 alkoxy group, a C.sub.1-6
alkoxyalkoxy group, an aryloxy group, an aralkyloxy group, a
halogenated C.sub.1-6 alkyl group, a hydroxy C.sub.1-6 alkyl group,
a cyano C.sub.1-6 alkyl group, a halogenated C.sub.1-6 alkoxy
group, a hydroxy C.sub.1-6 alkoxy group, a cyano C.sub.1-6 alkoxy
group, a C.sub.1-6 acyl group, a nitro group, an optionally
substituted amino group, an optionally substituted amide group, a
mercapto group and a C.sub.1-6 thioalkoxy group, and preferably a
halogen atom, a hydroxyl group and a nitrile group may be
proposed.
[0040] The "substituents" such as "halogen atom", "C.sub.1-6 alkyl
group", "C.sub.3-8 cycloalkyl group", "C.sub.1-6 alkoxy group",
"C.sub.1-6 alkoxyalkoxy group", "halogenated C.sub.1-6 alkyl
group", "hydroxy C.sub.1-6 alkyl group", "cyano C.sub.1-6 alkyl
group", "halogenated C.sub.1-6 alkoxy group", "hydroxy C.sub.1-6
alkoxy group", "cyano C.sub.1-6 alkoxy group", "C.sub.1-6 acyl
group", "optionally substituted amino group", "optionally
substituted amide group", "mercapto group" or "C.sub.1-6 thioalkoxy
group" have the same meanings as defined above, respectively.
Moreover, the "aryl group" in the above-mentioned "aryloxy group"
means a cyclic hydrocarbon group constituting an aromatic ring. For
example, monocyclic, dicyclic or tricyclic aryl groups such as a
phenyl group, an indenyl group, a naphthyl group, an azulenyl
group, a heptalenyl group, an anthnyl group or a phenanthrenyl
group may be proposed. The "aryloxy group" means a group in which
the above-mentioned aryl group is bound to an oxygen atom. For
example, a phenoxy group and naphthyloxy group may be proposed. The
above-mentioned "aralkyloxy group" means a group in which a group
having the same meaning as the above-mentioned aryl group is bound
to a C.sub.1-6 alkyl group, and the resulting arylalkyl group is
further bound to an oxygen atom. For example, a benzyloxy group, a
phenylethoxy group, a phenylpropoxy group and naphthylmethoxy group
may be proposed.
[0041] As R.sup.2, preferably a hydrogen atom or an optionally
substituted C.sub.1-6 alkyl group, more preferably a hydrogen atom
or a methyl group, ethyl group, n-propyl group, iso-propyl group,
2-methyl-1-propyl group and tert-butyl group which may be
respectively substituted, and further preferably a hydrogen atom
may be proposed.
[0042] The above description has discussed the definitions of
R.sup.1 and R.sup.2, and R.sup.1 and R.sup.2 may be independent of
each other and each may be a group based upon the respective
definitions, and it goes without saying that the combination
thereof is not limited. As the more preferable mode of the compound
(I) of the present invention, the case where R.sup.1 is a group
represented by the formula: 13
[0043] (in the formula, each symbol has the same meaning as defined
above); and R.sup.2 is a hydrogen atom or an optionally substituted
C.sub.1-6 alkyl group may be proposed. As the further preferable
mode, the case where R.sup.1 is a
5,6-dimethoxy-2-fluoro-1-indanon-2-yl group; and R.sup.2 is a
hydrogen atom or a methyl group, ethyl group, n-propyl group,
iso-propyl group, 2-methyl-1-propyl group or t-butyl group which
may be substituted, respectively may be proposed. As the most
preferable mode, the case where R.sup.1 is
5,6-dimethoxy-2-fluoro-1-indanon-2-yl group; and R.sup.2 is a
hydrogen atom may be proposed. As the most preferable mode of the
compound (I) of the present invention, for example, any compound
selected from 4-[(5,6-dimethoxy-2-fluoro-1-indanon)-
-2-yl]methylpiperidine,
4-[(5,6-dimethoxy-2-fluoro-1-indanon)-2-yl]methyl--
1-methylpiperidine,
4-[(5,6-dimethoxy-2-fluoro-1-indanon)-2-yl]methyl-1-(1-
-methylethyl)piperidine and
4-[(5,6-dimethoxy-2-fluoro-1-indanon)-2-yl]met-
hyl-1-(2-methylpropyl)piperidine may be proposed, however, it goes
without saying that the present invention is not limited by
them.
[0044] In the specification of the present application, the "salt"
refer to a pharmacologically acceptable salt, and is not
particularly limited, as long as it forms an addition salt with the
compound of the present invention. For example, hydrohalogenates
such as hydrofluoride, hydrochloride, hydrobromide or hydroiodide;
inorganic acid salts such as sulfate, nitrate, perchlorate,
phosphate, carbonate or bicarbonate; organic carboxylates such as
acetate, oxalate, maleate, tartrate or fumarate; organic sulfonates
such as methanesulfonate, trifluoromethanesulfonate,
ethanesulfonate, benzenesulfonate, toluenesulfonate or
camphor-sulfonate; amino acid salts such as aspertate or glutamate;
amine salts such as trimethylamine salt, triethylamine salt,
procaine salt, pyridine salt or phenethylbenzylamine salt; alkali
metal salts such as sodium salt or potassium salt; and alkali earth
metal salts such as magnesium salt or calcium salt, and preferably
hydrochloride and oxalate may be proposed.
[0045] As the producing process of the compound of the present
invention, various methods may be proposed. As the typical method,
for example, the following method may be proposed. That is, the
compound (I) of the present invention can be produced by
fluorinating a 4-substituted piperidine compound represented by the
formula (II): 14
[0046] (in the formula, R.sup.11 represents any one group selected
from the following substituents: 1516
[0047] (in the formula, R.sup.3, R.sup.4, R.sup.5, R.sup.6,
R.sup.7, m, p and a bond represented by the partial structure have
the same meanings as defined above, respectively); and R.sup.2 has
the same meaning as defined above) and, if necessary, converting it
into a salt. In the producing process, a preferable result can be
obtained by reacting with a base first, and then reacting with a
fluorinating agent, in general. As the base to be used, a strong
base is preferable, and the kind thereof is not particularly
limited. For example, lithium bis(trimethylsilyl)amide, n-butyl
lithium, lithium diisopropylamide, sodium amide, sodium hydride,
sodium methoxide, sodium ethoxide, potassium t-butoxide, sodium
hydroxide, potassium hydroxide etc. may be proposed. As the
fluorinating agent to be used, for example,
N-fluorobenzenesulfonimide (NFSI, CAS Registration No:
133745-75-2), 3-cyclohexyl-2-fluoro-2,3-dihydro-3-methyl-
-1,1-dioxide-1,2-benzisothiazole (CMIT-F, CAS Reg. Nos:
186806-24-6, 196106-79-3),
2-fluoro-3,3-dimethyl-2,3-dihydro-1,2-benzisothiazole-1,1-d- ioxide
(CAS Reg. No: 124170-23-6), diethylaminosulfur trifluoride (DAST,
CAS Reg. No: 38078-09-0),
N,N-diethyl-1,1,2,3,3,3-hexafluoropropylamine (Ishikawa Reagent),
hydrogen fluoride, tetraalkylammonium fluoride, potassium fluoride,
cesium fluoride, hydrogen fluoride-pyridine (Olah Reagent) etc. may
be proposed. Preferably, N-fluorobenzenesulfonimide,
3-cyclohexyl-2-fluoro-2,3-dihydro-3-methyl-1,1-dioxide-1,2-benzisothiazol-
e,
2-fluoro-3,3-dimethyl-2,3-dihydro-1,2-benzisothiazole-1,1-dioxide
may be proposed. The solvent to be used is not particularly limited
as long as it is inactive to the above-mentioned strong base and
fluoridating agent. For example, tetrahydrofuran (THF),
1,2-dimethoxyethane (DME, ethylene glycol dimethyl ether), ethyl
ether, isopropyl ether, butyl ether, 1,3-dioxane, 1,4-dioxane,
1,3-dioxolane, benzene, toluene, xylene, cyclohexane, n-hexane,
n-pentane, n-octane, petroleum ether etc. may be proposed, and
these solvents may be used singly or as a mixture of two or
more.
[0048] Here, the 4-substituted piperidine compound represented by
the above formula (II) may be produced by the method similar to or
in accordance with those described in, for example, JP-A64-79151
(EP-A1 296560), JP-A 55-140149 (EP-A1 487071), JP-A 6-500794, JP-A
6-510788, JP-A 6-508904, JP-A 5-279355, JP-A 5-320160, JP-A
6-116237, JP-A 6-41070 etc.
[0049] Here, material compounds in the production of the compound
of the present invention may be a salt and a hydrate, and are not
particularly limited as long as they are inert to the reaction.
Moreover, when the compound (I) of the present invention is
obtained as a free form, it may be converted into a salt form that
may be formed by the above-mentioned compound (I) in a conventional
method. Further, various isomers of the compound (I) of the present
invention (for example, geometric isomers, optical isomers due to
an asymmetric carbon, stereoisomers and tautomers) can be purified
and isolated by using conventional separating means such as
recrystallization, a diastereomer salt method, an enzymolysis
method and various chromatographies (such as thin layer
chromatography, column chromatography or gas chromatography).
[0050] The compound represented by the above formula (I) of the
present invention, a salt thereof or a hydrate of them may be
prepared in a conventional method. As the preferable agent forms
include tablets, powders, fine granules, granules, coated tablets,
capsules, syrup, troche, inhalant, suppositories, injections,
ointments, eye ointments, ophthalmic solutions, nasal drops, ear
drops, cataplasms and lotions. In preparing, generally used
fillers, binders, disintegrating agents, lubricants, coloring
agents, flavoring agents, and if necessary, a stabilizer,
emulsifier, absorbefacients, surfactant, pH adjusting agent,
preservative, antioxidant etc. may be used. It may be prepared in a
conventional method by blending components generally used as
materials for pharmaceutical preparations. As these components, for
example, (1) animal and vegetable oils such as soybean oil, beef
tallow or synthetic glyceride; (2) hydrocarbons such as fluid
paraffin, squalane or solid paraffin; (3) ester oils such as
octyldodecyl myristate or isopropyl myristate; (4) higher alcohols
such as setostearyl alcohol or behenyl alcohol; (5) silicon resin;
(6) silicon oil; (7) surfactants such as polyoxyethylene fatty acid
ester, sorbitan fatty acid ester, glycerin fatty acid ester,
polyoxyethylene sorbitan fatty acid ester, polyoxyethylene
hydrogenated castor oil or polyoxyethylene-polyoxypropyle- ne block
copolymer; (8) water soluble polymers such as hydroxyethyl
cellulose, polyacrylic acid, carboxyvinyl polymer, polyethylene
glycol, polyvinyl pyrrolidone or methyl cellulose; (9) lower
alcohols such as ethanol or isopropanol; (10) polyhydric alcohols
such as glycerin, propylene glycol, dipropylene glycol or sorbitol;
(11) saccharides such as glucose or saccharose; (12) inorganic
powders such as silicic anhydride, aluminum magnesium silicate or
aluminum silicate; (13) purified water etc. may be proposed.
[0051] 1) As the fillers, for example, lactose, corn starch,
saccharose, glucose, mannitol, sorbitol, crystalline cellulose,
silicon dioxide etc.; 2) as the binders, for example, polyvinyl
alcohol, polyvinyl ether, methyl cellulose, ethyl cellulose, gum
arabic, gum tragacanth, gelatin, shellac, hydroxypropyl cellulose,
hydroxypropylmethyl cellulose, polyvinyl pyrrolidone, polypropylene
glycol-polyoxyethylene block polymer, megulumine, calcium citrate,
dextrin, pectin etc.; 3) as the disintegrating agents, for example,
starch, agar, gelatin powder, crystalline cellulose, calcium
carbonate, sodium hydrogencarbonate, calcium citrate, dextrin,
pectin, carboxymethyl cellulose, calcium etc.; 4) as the
lubricants, for example, magnesium stearate, talc, polyethylene
glycol, silica, hydrogenated vegetable oil etc.; 5) as the coloring
agents, those which are permitted to add to pharmaceutical
preparations; 6) as the flavoring agents, cocoa powder, menthol,
aromatic powder, menthol oil, borneol, cinnamon powder etc.; and 7)
as the antioxidant, ascorbic acid, .alpha.-tocopherol etc. which
are permitted to add to drugs may be used, respectively.
[0052] 1) Oral preparation is prepared by adding fillers and, if
necessary, a binder, a disintegrating agent, a lubricant, a
coloring agent, a flavoring agent etc. to the compound of the
present invention or a salt thereof have been added to the compound
or a salt thereof, and then it is prepared into a form of powders,
fine granules, granules, tablets, coated tablets, capsules etc., in
a conventional method. 2) In the case of tablets and granules,
these may of course be sugar-coated, gelatin-coated and other, if
necessary. 3) In the case of liquid preparations such as syrup,
injection, eye ointments etc., a pH adjusting agent, a dissolving
agent and an isotonic agent etc. and, if necessary, a solubilizer,
a stabilizer, a buffer, a suspending agent, an antioxidant etc. are
added, and then prepared in a conventional method. In preparing the
liquid, it may be prepared as a freeze drying product, and the
injection may be administered intravenously, subcutaneously and by
intramascular injection. Preferable examples of the suspending
agent include methyl cellulose, polysorbate 80, hydroxyethyl
cellulose, gum arabic, tragacanth powder, sodium carboxymethyl
cellulose, polyoxyethylene sorbitan monolaurate etc.; preferable
examples of the solubilizer include polyoxyethylene hydrogenated
castor oil, polysorbate 80, nicotinamide, polyoxyethylene sorbitan
monolaurate etc.; preferable examples of the stabilizer include
sodium sulfite, sodium metasulfite, ether etc.; preferable examples
of the preservative include methyl paraoxybenzoate, ethyl
paraoxybenzoate, sorbic acid, phenol, cresol, chlorocresol etc.
Further, in the case of 4) the externally applied agents, the
producing process is not particularly limited, and these may be
produced in a conventional method. As the base materials to be
used, various materials commonly used in drugs, quasi-drugs,
cosmetics, etc. may be used. For example, base materials such as
animal and vegetable oils, mineral oils, ester oils, waxes, higher
alcohols, fatty acids, silicone oil, surfactants, phospholipids,
alcohols, polyhydric alcohols, water-soluble polymers, clay
minerals or purified water may be proposed, and if necessary, pH
adjusting agents, antioxidants, chelating agents, preservatives,
coloring agents, flavoring agents etc. may be added thereto.
Moreover, if necessary, components having a differentiation
inducing effect, bloodstream promoting agents, germicides,
antiphlogistics, cell activators, vitamins, amino acids,
moisturizers, keratin solubilizers etc. may also be added.
[0053] The dose of the medicament according to the present
invention varies depending on the degree of symptoms, age, sex,
weight, administration form, kind of salt, difference in
sensitivity to the medicine, specific type of the disease and the
like, and in case of an adult, it is orally administered in amount
of generally 30 .mu.g to 1000 mg, preferably 100 .mu.g to 500 mg
and more preferably 100 .mu.g to 100 mg, and approximately 1 to
3000 .mu.g/kg, preferably 3 to 1000 .mu.g/kg in the case of
injection administration, at one time or in several portions per
day.
[0054] The present invention makes it possible to provide a novel
compound represented by the above formula (I), a salt thereof and
an hydrate of them. The compound represented by the above-mentioned
formula (I) of the present invention, a salt thereof or a hydrate
of them exhibits a superior acetylcholinesterase inhibitory action.
Therefore, it is useful as an agent for treating, preventing or
improving various senile dementia, cerebrovascular dementia or
attention deficit hyperactivity disorder, and is especially useful
as an agent for treating, preventing or improving Alzheimer-type
senile dementia.
EXAMPLES
[0055] The best mode of the compound according to the present
invention represented by the above formula (I) or a salt thereof
are shown below. The following Reference Examples, Examples and
Test Examples are exemplary, and the compound of the present
invention or a salt thereof is not limited to the following
specific examples in any case. One skilled in the art may make
various variations of theses specific examples and claims of the
present invention to carry out the present invention. Further,
these variations are included in the scope of the claims of the
present invention.
Example 1
[0056] 4-[(5,6-Dimethoxy-2-fluoro-1-indanon)-2-yl]methylpiperidine
hydrochloride 17
[0057] In 5 ml of 1,2-dichloroethane was dissolved 0.25 g (0.63
mmol) of
1-benzyl-4-[(5,6-dimethoxy-2-fluoro-1-indanon)-2-yl]methylpiperidine,
followed by adding 0.81 ml (0.77 mmol) of
1-chloroethylchloroformate. After heating under reflux for one
hour, it was evaporated. 5 ml of methanol was added thereto,
followed by heating under reflux for further 40 minutes. It was
evaporated, and the resulting residue was recrystallized from
methanol-diethyl ether, to obtain 0.19 g of the title compound
(free form) as pale yellowish white crystals (yield; 98%). The
physicochemical data of the free form of the title compound are
shown below.
[0058] Melting point: 234-238.degree. C. (decomposition)
.sup.1H-NMR (400 Mz: CD.sub.3OD) .delta. 1.45-1.60 (2H,m),
1.77(1H,ddd,J=6 Hz, J=14.8 Hz,J=30 Hz), 1.94-2.14(4H,m),
2.94-3.06(2H,m), 3.22-3.48(4H,m), 3.86(3H,s), 3.95(3H,s),
7.07(1H,s), 7.18(1H,s).
[0059] The product was converted into hydrochloride in a
conventional method and recrystallized from 95%
ethanol/tert-butylmethyl ether, to give the title compound as pale
yellowish white crystals. The physicochemical data of the title
compound (hydrochloride) are shown below.
[0060] Melting point: >240.degree. C. (decomposition)
.sup.1H-NMR (400 Mz: CDCl.sub.3) .delta.1.72-2.17(7H,m),
2.91(1H,bs), 3.19-3.39 (2H,m), 3.48(2H,bs), 3.92(3H,s), 3.99(3H,s)
6.84(1H,s), 7.18(1H,s), 9.31(1H,bs), 9.56(1H,s). ESI-MS: m/z=308
(M+H.sup.+).
Example 2
[0061]
4-[(5,6-Dimethoxy-2-fluoro-1-indanon)-2-yl]methyl-1-methylpiperidin-
e hydrochloride 18
[0062] To 68 mg (0.20 mmol) of
4-[(5,6-dimethoxy-2-fluoro-1-indanon)-2-yl]- methylpiperidine
hydrochloride were added 0.052 ml (1.39 mmol) of formic acid and
0.10 ml (1.38 mmol) of 37% formaldehyde. After heating at
80.degree. C. for 3 hours, it was allowed to be cooled to room
temperature and 30 ml of ethyl acetate was added thereto. It was
washed with 30 ml of aqueous 1N sodium hydroxide and 30 ml of
brine, dried (MgSO.sub.4) and then evaporated. The resulting
residue was purified by using fractionating thin layer
chromatography (methylene chloride/methanol), to give 34 mg of the
title compound (free form) as a pale yellow oil (yield; 53%). The
product was converted into hydrochloride in a conventional method
and recrystallized from ethanol/tert-butylmethyl ether, to give the
title compound as pale yellowish white crystals. The
physicochemical data of the title compound (hydrochloride) are
shown below.
[0063] Melting point: 215-220.degree. C. (decomposition)
.sup.1H-NMR (400 Mz: CDCl.sub.3) .delta.: 1.80-2.27(7H,m),
2.72-2.86(2H,m), 2.80(3H,s), 3.23(1H,dd,J=9.6 Hz,J=16.8 Hz),
3.32(1H,dd,J=17.6 Hz,J=38.4 Hz), 3.53(2H,t,J=12.8 Hz), 3.92(3H,s),
4.00 (3H,s), 6.85 (1H,s), 7.17 (1H,s). (No protons of hydrochloric
acid were observed). ESI-MS: m/z=322 (M+H.sup.+).
Example 3
[0064]
4-[(5,6-Dimethoxy-2-fluoro-1-indanon)-2-yl]methyl-1-(1-methylethyl)-
piperidine hydrochloride 19
[0065] In 3 ml of DMF was dissolved 50 mg (0.15 mmol) of
4-[(5,6-dimethoxy-2-fluoro-1-indanon)-2-yl]methylpiperidine
hydrochloride, followed by adding 0.049 ml (0.35 mmol) of
triethylamine and 0.016 ml (0.17 mmol) of 2-bromopropane. After
heating at 70.degree. C. for 6 hours, it was allowed to be cooled
to room temperature and 30 ml of ethyl acetate was added thereto.
It was washed with 30 ml of water and 30 ml of brine, dried
(MgSO.sub.4) and then evaporated. The resulting residue was
purified by a fractionating thin layer chromatography (methylene
chloride/methanol), to give 13 mg of the title compound (free form)
as a pale yellow oil (yield; 26%). The product was converted into
hydrochloride in a conventional method and solidified by using
diethyl ether, to give the title compound as a pale yellowish white
amorphous. The physicochemical data of the title compound
(hydrochloride) are shown below.
[0066] .sup.1H-NMR (400 Mz: CDCl.sub.3) .delta.: 1.43(6H,d,J=5.6
Hz), 1.81(1H,bd,J=12.8 Hz), 1.90-1.95(1H,m), 1.96-2.01(1H,m),
2.07-2.32(4H,m), 2.69-2.86(2H,m), 3.18-3.50(5H,m), 3.92(3H,s),
3.99(3H,s), 6.84(1H,s), 7.17(1H,s), 11.55(1H,bs). ESI-MS: m/z=350
(M+H.sup.+).
Example 4
[0067]
4-[(5,6-Dimethoxy-2-fluoro-1-indanon)-2-yl]methyl-1-(2-methylpropyl-
)piperidine hydrochloride 20
[0068] In the same manner as in Example 3, the title compound (free
form) was obtained as a pale yellow oil (yield; 40%). The product
was converted into hydrochloride in a conventional method and
recrystallized from ethanol/tert-butylmethyl ether, to give the
title compound as pale yellowish white crystals. The
physicochemical data are shown below.
[0069] Melting point: 220-225.degree. C. (decomposition)
.sup.1H-NMR(400 Mz: CDCl.sub.3) .delta.: 1.15(6H,d,J=6.8 Hz),
1.78(1H,bd,J=13.2 Hz), 1.93(1H,bs), 1.99(1H,bs), 2.08-2.40(5H,m),
2.62-2.78(2H,m), 2.80(2H,d,J=6.4 Hz), 3.23(1H,dd,J=9.6 Hz,J=16.8
Hz), 3.31(1H,dd,J=17.6 Hz,J=38.8 Hz), 3.58(2H,bt,J=14 Hz),
3.92(3H,s), 3.99(3H,s), 6.84(1H,s), 7.17(1H,s), 11.61(1H,bs).
ESI-MS: m/z=364 (M+H.sup.+).
[0070] Hereinbelow, a pharmacological test example is shown to
illustrate the usefulness of the compound of the present invention
as a medicament.
[0071] Inhibitory Effect on Acetylcholinesterase In Vitro
[0072] Using a rat brain homogenate as a source of
acetylcholinesterase, the esterase activity was determined in
accordance with the method of Ellman et al.sup.1).
Acethylthiocholine (as a substrate), a test compound and DTNB
(5,5'-dithiobis(2-nitrobenzoic acid)) were added to the mouse brain
homogenate, and then incubated. Then, the resulting yellow product
produced by the reaction of the resulting thiocholine with DTNB was
determined for the change in absorbance at 412 nm, to determine the
acethylcholinesterase activity. The acetylcholinesterase inhibitory
action of each test compound was determined in terms of 50%
inhibitory concentration (IC.sub.50). Here, the test compounds were
respectively dissolved in physiological saline, and used. .sup.1);
Ellman. G. L., Courtney, K. D., Andres, V. and Featherstone, R.
M.,(1961), Biochem. Pharmacol., 7, 88 to 95.
[0073] In the above-mentioned test examples, the compound
represented by the above-mentioned formula (I) of the present
invention, a salt thereof or a hydrate of them showed significant
acetylcholinesterase inhibitory actions.
* * * * *